Compare Novartis AG (NVS) vs Vanguard Global ex-US Real Estate Index Fd ETF (VNQI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novartis AG vs Vanguard Global ex-US Real Estate Index Fd ETF — how do they compare? Novartis AG trades at $152.66 (market cap $295.37B), while Vanguard Global ex-US Real Estate Index Fd ETF trades at $45.72. The key difference: Novartis AG pays a 3.07% dividend while Vanguard Global ex-US Real Estate Index Fd ETF pays none, and Novartis AG is trading nearer its 52-week high, Vanguard Global ex-US Real Estate Index Fd ETF nearer its low. Which is the better fit depends on your goals.
| NVS | VNQI | |
|---|---|---|
Market Cap | $295.37B | — |
Sector | Health | — |
52-Week High | $168.62 | $50.76 |
52-Week Low | $119.31 | $43.26 |
Enterprise Value | $336.69B | — |
Dividend Yield | 3.07% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Novartis AG (NVS) trades at $152.54, down 2.71% on the day, with a neutral technical signal. The company reported strong Q2 2026 earnings, beating EPS estimates of $2.17 with $2.41 actual, driven by oncology drug performance. Revenue for 2025 was $56.67 billion with a net income margin of 22.5%. Analyst consensus is mixed with 24% buy, 68% hold, and 8% sell ratings among 25 analysts.
The outlook is cautiously optimistic, supported by a robust drug pipeline and recent earnings strength, but risks include generic competition pressure on key drugs like Entresto and rising debt levels. The stock presents a stable investment opportunity with solid profitability, though growth may be tempered by industry headwinds.
VNQI (Vanguard Global ex-U.S. Real Estate ETF) trades at $45.82, up 0.57% with a bullish technical signal from moving averages. The ETF provides diversified international real estate exposure across 30+ countries outside the US, featuring a higher dividend yield than domestic alternatives. Recent news highlights comparisons with US-focused REIT ETFs, emphasizing VNQI's global diversification benefits and competitive expense ratio.
The outlook remains positive given international real estate diversification and income appeal, though performance has lagged US counterparts. Key risks include currency fluctuations, geopolitical factors affecting foreign markets, and interest rate sensitivity. Institutional activity shows mixed signals with recent significant position reductions by some funds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novartis AG
Novartis develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.
Read more on NVS →About Vanguard Global ex-US Real Estate Index Fd ETF
The fund employs an indexing investment approach designed to track the performance of the S&P Global ex-US Property Index, a float-adjusted, market-capitalization-weighted index that measures the equity market performance of international real estate stocks in both developed and emerging markets. The index is composed of stocks of publicly traded equity real estate investment trusts (known as REITs) and certain real estate management and development companies (REMDs).
Read more on VNQI →
